Literature DB >> 27998016

Elucidating the role of hyposalivation and autoimmunity in oral candidiasis.

M Billings1, B A Dye2, T Iafolla2, M Grisius1, I Alevizos1.   

Abstract

INTRODUCTION: Oral candidiasis (OC) is a potential oral complication in Sjögren's syndrome (SS). Some studies indicate that the low stimulated salivary flow and not low unstimulated salivary flow is associated with OC in SS, while others report that the underlying autoimmune disorders contribute to OC, based solely on correlation coefficients. Given the conflicting and limited existing evidence, we purposed to ascertain the role of both salivary gland dysfunction (hyposalivation based on unstimulated and stimulated flow rates) and autoimmunity (SS, other autoimmune disorders) in OC among those with SS, other salivary gland dysfunction, and non-salivary gland dysfunction controls (NSGD).
METHODS: A nested case-control study was designed within a larger NIH/NIDCR cohort. Descriptive analyses, nonparametric tests, comparative analyses, and multivariate logistic regression analyses were undertaken.
RESULTS: Data on 1526 subjects (701 SS, 247 ISS, 355 Sicca, and 223 NSGD) were obtained from the source cohort of 2046 and analyzed for this study. The median whole unstimulated salivary flow rate (WUS, ml 15 min-1 ) was lower in SS (0.8, interquartile range (IQR) 1.8) compared to ISS (5.5, IQR: 5.2, P < 0.001) and NSGD (3.8, IQR: 3.8, P < 0.001) but comparable with that of Sicca (1.0, IQR: 1.5, P = 0.777) participants. The median total stimulated salivary flow rate (TSS, ml 15 min-1 ) was lowest in SS (7.0, IQR: 12.4, P < 0.001) compared to other groups. Of the 45 OC cases in this cohort, 71.1% (n = 32) were from the SS group. The prevalence of OC was highest in the SS group (4.6%, P = 0.008). SS group had twice the risk of OC than NSGD (OR = 2.2, 95%CI: 1.1-4.2, P = 0.02) and Sicca (OR = 2.2, 95% CI: 1.0-4.8, P = 0.03), adjusting for confounders; hyposalivation [WUS (OR = 5.1, 95%CI: 2.5-10.4, P < 0.001), TSS (OR = 1.9, 95%CI: 1.0-3.5, P = 0.04)], history of other autoimmune disorders (OR = 4.4, 95%CI: 1.7-11.3, P = 0.002), medications for extraglandular manifestations (OR = 2.3, 95%CI: 1.1-4.9, P = 0.03), and diabetes mellitus (4.2, 95%CI: 1.2-15.2, P = 0.02) were independent predictors of OC; females had a lower risk than males (OR = 0.29, 95%CI: 0.13-0.67, P = 0.004). Age, race, anti-SSA/SSB autoantibodies, focus score, other medications, anxiety, fatigue, cigarette smoking, alcohol, and caffeine use were not associated with oral candidiasis.
CONCLUSION: Salivary gland dysfunction (hyposalivation with WUS being a stronger predictor than TSS) and autoimmunity (SS, other autoimmune disorders, medications, i.e., DMARDS) are both independent predictors of OC. Diabetes mellitus is an independent predictor of OC among those with salivary gland dysfunction. Our findings suggest that these independent predictors should be considered in the prevention and management of OC in this population. © Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Sjogren's syndrome; autoimmunity; hyposalivation; oral Candidiasis

Mesh:

Year:  2017        PMID: 27998016      PMCID: PMC5340613          DOI: 10.1111/odi.12626

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  26 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  The yeasts of the normal mouth and their relation to salivary acidity.

Authors:  G YOUNG; H G RESCA; M T SULLIVAN
Journal:  J Dent Res       Date:  1951-06       Impact factor: 6.116

3.  Changes in the oral flora in Sjögren's syndrome.

Authors:  T W MacFarlane; D K Mason
Journal:  J Clin Pathol       Date:  1974-05       Impact factor: 3.411

4.  In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.

Authors:  H Situ; L A Bobek
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 5.  Chronic mucocutaneous candidiasis and congenital susceptibility to Candida.

Authors:  Erik Glocker; Bodo Grimbacher
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-12

6.  Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis.

Authors:  D P Steensma; A Tefferi; C R Weiler
Journal:  Mayo Clin Proc       Date:  2000-08       Impact factor: 7.616

7.  Fungal load and candidiasis in Sjögren's syndrome.

Authors:  Lida Radfar; Yvonne Shea; Steven H Fischer; Vidya Sankar; Rose Anne Leakan; Bruce J Baum; Stanley R Pillemer
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2003-09

8.  Anticandidal activity of major human salivary histatins.

Authors:  T Xu; S M Levitz; R D Diamond; F G Oppenheim
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

9.  MUC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action.

Authors:  Libuse A Bobek; Hongsa Situ
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 10.  Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy.

Authors:  Anna R Huppler; Shrinivas Bishu; Sarah L Gaffen
Journal:  Arthritis Res Ther       Date:  2012-07-23       Impact factor: 5.156

View more
  6 in total

Review 1.  Tissue-Specific Immunity at the Oral Mucosal Barrier.

Authors:  Niki M Moutsopoulos; Joanne E Konkel
Journal:  Trends Immunol       Date:  2017-09-08       Impact factor: 16.687

2.  Integrated Analysis of Clinical and Microbiome Risk Factors Associated with the Development of Oral Candidiasis during Cancer Chemotherapy.

Authors:  Patricia I Diaz; Bo-Young Hong; Amanda K Dupuy; Linda Choquette; Angela Thompson; Andrew L Salner; Peter K Schauer; Upendra Hegde; Joseph A Burleson; Linda D Strausbaugh; Douglas E Peterson; Anna Dongari-Bagtzoglou
Journal:  J Fungi (Basel)       Date:  2019-06-13

Review 3.  Galectin-3, Possible Role in Pathogenesis of Periodontal Diseases and Potential Therapeutic Target.

Authors:  Milica Velickovic; Aleksandar Arsenijevic; Aleksandar Acovic; Dragana Arsenijevic; Jelena Milovanovic; Jelena Dimitrijevic; Zeljko Todorovic; Marija Milovanovic; Tatjana Kanjevac; Nebojsa Arsenijevic
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

Review 4.  Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.

Authors:  Maja Ptasiewicz; Dominika Bębnowska; Paulina Małkowska; Olga Sierawska; Agata Poniewierska-Baran; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Renata Chałas
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

5.  Hyposalivation and oral candidiasis-A short review.

Authors:  N Aravindha Babu; N Anitha
Journal:  J Oral Maxillofac Pathol       Date:  2022-06-28

Review 6.  Periodontal Disease: The Good, The Bad, and The Unknown.

Authors:  Lea M Sedghi; Margot Bacino; Yvonne Lorraine Kapila
Journal:  Front Cell Infect Microbiol       Date:  2021-12-07       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.